[New drug approval: Pembrolizumab - Neoadjuvant/adjuvant treatment for localized high-risk triple negative breast cancer]

Bull Cancer. 2022 Oct;109(10):988-989. doi: 10.1016/j.bulcan.2022.06.006. Epub 2022 Jul 22.
[Article in French]
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Chemotherapy, Adjuvant
  • Drug Approval
  • Female
  • Humans
  • Neoadjuvant Therapy
  • Triple Negative Breast Neoplasms* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • pembrolizumab